Skip to main content
Epocrates Online
Contact us
Explore features
Reach clinicians
Buy now
By
vgreene
, 15 January, 2015
CHA<sub>2</sub>DS<sub>2</sub>-VASc ≥2 (including hx stroke/TIA)
By
vgreene
, 15 January, 2015
CHA<sub>2</sub>DS<sub>2</sub>-VASc 1
By
vgreene
, 15 January, 2015
CHA<sub>2</sub>DS<sub>2</sub>-VASc 0
By
vgreene
, 15 January, 2015
Rate-control approach desired (d/t pt preference, etc)
By
vgreene
, 15 January, 2015
CHA<sub>2</sub>DS<sub>2</sub>-VASc ≥2 (including hx stroke/TIA)
By
vgreene
, 15 January, 2015
CHA<sub>2</sub>DS<sub>2</sub>-VASc 1
By
vgreene
, 15 January, 2015
CHA<sub>2</sub>DS<sub>2</sub>-VASc 0
By
vgreene
, 15 January, 2015
Desogestrel 0.15 mg/EE 20 mcg
By
vgreene
, 15 January, 2015
Desogestrel 0.15 mg/EE 20 mcg
By
vgreene
, 14 January, 2015
Norethindrone 1 mg/EE 20 mcg
Pagination
First page
Previous page
…
Page
4010
Page
4011
Page
4012
Page
4013
Current page
4014
Page
4015
Page
4016
Page
4017
Page
4018
…
Next page
Last page
About Us
Company Overview
Media Relations
Contact
Editorial Policy
Editorial Process
Third-Party Sponsorship Policy
athenahealth
Products
Core Products
Mobile CME
Product Licenses
Business Solutions
Pharma
Market Research
Institutions
Support
Support Center
Install
My Account
Stay Connected
Facebook
Twitter
YouTube